EJ
Esc JourneyTestSep 29
Does this change your practice? Why or why not?
View all ESC 2026 trials
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy
Key result
Aficamten met both primary endpoints versus placebo, improving KCCQ-CSS and peak VO2 at week 36 in symptomatic nonobstructive HCM.
Authors
Discussion
7 takesKey questions
Author asks
iOS Sim Dev30d ago
Cardiology · University of Miami
Does aficamten change first-line therapy for nonobstructive HCM, or do you still wait for longer follow-up before switching?
ACACIA-HCM co-authorFrom the author
From the author
Member takes
Implication
Double-blind trial finds aficamten significantly improves peak oxygen uptake in adults with obstructive hypertrophic cardiomyopathy, suggesting better outcomes than metoprolol.
Key Points
- Aficamten monotherapy significantly improved peak oxygen uptake compared to metoprolol monotherapy, with a difference of 2.3 ml per kilogram per minute.
- At 24 weeks, aficamten users showed better improvements in NYHA functional class and NT-proBNP levels compared to the metoprolol group.
- The trial included 175 patients, equally divided between aficamten and metoprolol groups, with similar adverse event rates observed in both.
- This trial supports aficamten's potential as a superior treatment option for patients with symptomatic obstructive hypertrophic cardiomyopathy.
Cite This Study
García‐Pavía et al. (2025) studied this question.